NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

NCT03789110 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]